What’s Next For Dr. Clay Siegall & Seattle Genetics

Fighting cancer is no easy task. Producing good medications that fights cancer surely isn’t easy as well, but there organizations out there that are willing to put in the time and effort. Seattle Genetics just so happens to be one of those organizations, and it has made an extremely huge impact on this industry. Seattle Genetics was co-founded by Dr. Clay Siegall back in the late 1990s. Dr. Siegall may be one of the most accomplished and well-celebrated professionals in the game. He has a heart of gold as well as a brilliant mind. When it comes to fighting cancer, this dynamic duo has outperformed other duos and here is why.

Antibody-drug conjugates have reshaped cancer research for the better. These advanced drugs are superior, especially when being compared to the predecessors of the past. Dr. Siegall has implemented strong, core principles into this advanced program, and these principles have produced a successful company. Seattle Genetics has a pipeline full of medications, and four out of the 20 medications has great potential to hit the market in future years. ADCETRIS, the company’s top drug, has earned well-over $300 million in a rather short period of time. ADCETRIS is now being used all around the world thanks to Dr. Siegall. By participating in strategic-licensing deals, ADCETRIS has been distributed to the public by many drug companies like Pfizer, Genentech and GlaxoSmithKlien. The company’s growth-trajectory has drastically increased by 46 percent since 2014. In 2016, the company’s sales reached up to $400 million.

Dr. Siegall’s influence on this company can’t be denied, and it can’t be questioned. He is the oil that keeps this engine running, and he is the glue that holds everything together. Seattle Genetics and Dr. Clay Siegall are looking to take this company to the next level via research, innovation and drug development.

April 11, 2018

Posted In: Drug Development